Business Standard

Kiran Mazumdar support for pharma

BS Reporter  |  Chennai/ Chandigarh 

Kiran Mazumdar-Shaw, CMD, Ltd, has said that both developed countries and emerging markets were now moving towards generic drugs. She added, with India emerging as biggest and low-cost generic producer, it provides a huge opportunity for India to gain from the growing generic drugs market. She has also demanded that the cost of capital needs to be subsidised, since pharmaceutical was a capital intensive business. Generic drugs is expected to be 40 per cent (value terms) of the global pharmaceutical market by 2015.

RECOMMENDED FOR YOU

Kiran Mazumdar support for pharma

Kiran Mazumdar-Shaw, CMD, Biocon Ltd, has said that both developed countries and emerging markets were now moving towards generic drugs. She added, with India emerging as biggest and low-cost generic producer, it provides a huge opportunity for India to gain from the growing generic drugs market. She has also demanded that the cost of capital needs to be subsidised, since pharmaceutical was a capital intensive business.

Kiran Mazumdar-Shaw, CMD, Ltd, has said that both developed countries and emerging markets were now moving towards generic drugs. She added, with India emerging as biggest and low-cost generic producer, it provides a huge opportunity for India to gain from the growing generic drugs market. She has also demanded that the cost of capital needs to be subsidised, since pharmaceutical was a capital intensive business. Generic drugs is expected to be 40 per cent (value terms) of the global pharmaceutical market by 2015.

image
Widgets Magazine
Widgets Magazine
Widgets Magazine

Advertisement